Urtoxazumab

Drug Profile

Urtoxazumab

Alternative Names: Anti-verotoxin of O-157; TMA-15

Latest Information Update: 24 May 2010

Price : $50

At a glance

  • Originator Teijin Pharma
  • Class Antidiarrhoeals; Monoclonal antibodies
  • Mechanism of Action Bacterial toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haemolytic uraemic syndrome

Most Recent Events

  • 16 Oct 2006 Data presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2006) have been added to the adverse events and pharmacokinetics sections
  • 12 Nov 2004 Phase-I clinical trials in Haemolytic uraemic syndrome in Japan (IV)
  • 12 Nov 2004 Phase-I clinical trials in Haemolytic uraemic syndrome in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top